The original AHA and still the most-studied chemical exfoliant in cosmetic science. Derived from sugarcane (cosmetic-grade is typically synthetic for purity). The smallest AHA molecule (76 Da) means fastest penetration and most dramatic resurfacing — and the highest irritation risk of the AHA family. 2025's clean-glycolic positioning is about smart pairing (with peptides, ceramides, niacinamide) rather than maximalist concentration wars.
Benefits
rapid, visible smoothing and tone evening
stimulates dermal GAGs and collagen at sustained use
improves penetration and efficacy of subsequent actives
Example uses
resurfacing toners and peels
body KP treatments
professional chemical peels
Mechanism of action
The smallest AHA (76 Da, two-carbon backbone), allowing the deepest stratum corneum penetration of the family. Disrupts corneodesmosome cohesion via sulphotransferase-mediated cleavage of cholesterol sulphate bridges, with sustained use upregulating fibroblast type I procollagen and dermal glycosaminoglycan synthesis through epidermal–dermal signalling. The aggressive penetration that drives its efficacy also drives its irritation profile — and is the basis for the 2024 EU restriction to 4% leave-on.
Clinical evidence · High
The most-studied AHA — decades of RCTs across photoaging, acne, melasma, post-inflammatory hyperpigmentation, and dermal-remodelling endpoints at OTC and in-office concentrations.
Effective concentration range
5–10% OTC (pH 3.5–4); 30–70% in-office peels; 4% leave-on cap in EU since 2024
Formulation notes
OTC effective at 5–10% (pH 3.5–4); derm in-office peels reach 30–70%. Pairs essentially with daily SPF, ceramides, and a barrier-repair night. Avoid same-routine layering with retinoids or strong vitamin C unless tolerance is established.
Watchouts
Highest PIH and stinging risk among common AHAs, especially on Fitzpatrick IV–VI; mandelic or lactic acid is often a smarter swap. Photosensitizing — SPF daily, non-negotiable.
The EU SCCS 2023 opinion and subsequent 4% leave-on cap is the live regulatory front — driven by sensitisation and dermal-irritation data the US has not yet acted on. PIH risk on Fitzpatrick IV–VI skin is real and clinically documented; mandelic acid is the dermatologically more defensible swap. Photosensitisation is well-established but consumer compliance with daily SPF remains the weak link.
Market positioning
Sold as the gold-standard 'glow' AHA. The marketing has slowly evolved post-EU restriction toward gentler alternatives, but glycolic still anchors the category — increasingly with a 'used responsibly' caveat the labels are starting to acknowledge.
Comedogenicity
0 / 5
Sensitisation risk
Moderate
INCI & aliases
Glycolic Acid
hydroxyacetic acid
Clean beauty perception
Established and trusted, but the clean conversation increasingly favors mandelic / PHA / lactic for sensitive and melanin-rich audiences.